AIDS Treatment NewsImportant note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Click here to return to AIDS Treatment News main menu
Print this Article


New Protease Inhibitor Atazanavir (Reyataz(TM)) Approved

AIDS TREATMENT NEWS Issue #392, June 27, 2003
John S. James

On June 20 the FDA approved the new once-a-day protease inhibitor atazanavir (brand name Reyataz), manufactured by Bristol-Myers Squibb. Atazanavir has little effect on the blood lipids cholesterol and triglycerides, and on May 13 the FDA's advisory committee of outside experts had unanimously recommended approval (see AIDS TREATMENT NEWS #391, May 30, 2003). Atazanavir can be taken as two pills once daily with food. In patients who have already had extensive HIV treatment, atazanavir may need to be "boosted" with a low dose of ritonavir (Norvir®) to maintain atazanavir blood levels (a reduced dose of atazanavir is recommended in this case; see Web site below to check current information). As with all other current antiretrovirals, atazanavir must be used as part of a combination regimen.

The advisory committee had some concern that the FDA was not be able to review all the data on treatment-experienced patients before the legal deadline for drug approval.

On June 20 Bristol-Myers Squibb, the manufacturer of atazanavir, issued a press release including the following cautions:

"Do not take REYATAZ if you are taking the following medicines: ergot derivatives, Versed®, Halcion®, Orap®, Propulsid®, Camptosar®, Vascor®, Crixivan®, Mevacor®, Zocor®, Rifampin, St. John's wort, AcipHex®, Nexium®, Prevacid®, Prilosec® or Protonix®. [Not a complete list -- JSJ] Do not use Viagra® while you are taking REYATAZ without first speaking with your healthcare provider. Discuss all prescription, non-prescription and herbal products you are taking or plan to take with your healthcare provider.

"Increases in indirect bilirubin (bilirubin is made by the liver) have been reported in patients taking REYATAZ. This may result in yellowing of the skin and/or eyes. These symptoms usually go away after you stop taking REYATAZ.

"Changes in the way your heart beats may occur when taking REYATAZ. If you get dizzy or lightheaded these could be symptoms of a heart problem. An increase of lactic acid in the blood (lactic acidosis), which can cause death, has been reported in patients taking REYATAZ with other anti-HIV medicines called nucleoside analogues. In some patients taking protease inhibitors, increased bleeding (in patients with hemophilia), diabetes and high blood sugar have occurred. If you have liver disease, including hepatitis B or C, your liver disease may get worse when you take anti-HIV medicines like REYATAZ."

For a current copy of the atazanavir "labeling" (information for doctors), see the full prescribing information at http://www.reyataz.com/ . Always use a current copy of the prescribing information, especially for a newly approved drug, since it will change as new information becomes available.

030627
ATN39202

Copyright © 2003 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org  http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .